A phase II dose-ranging study of mirabegron in patients with overactive bladder

Adverse Event Assessment of Antimuscarinics for Treating Overactive Bladder: A Network Meta-Analytic Approach

(2011) Thomas M. Kessler et al.   PLoS One

Validity and reliability of the patient’s perception of intensity of urgency scale in overactive bladder

(2010) Rufus Cartwright et al.   BJU INTERNATIONAL

Cardiovascular morbidity, heart rates and use of antimuscarinics in patients with overactive bladder

(2009) Karl-Erik Andersson et al.   BJU INTERNATIONAL

The overlap of storage, voiding and postmicturition symptoms and implications for treatment seeking in the USA, UK and Sweden: EpiLUTS

(2009) Chris C. Sexton et al.   BJU INTERNATIONAL

Patient-reported reasons for discontinuing overactive bladder medication

(2009) Joshua S. Benner et al.   BJU INTERNATIONAL

The Effects of Antimuscarinic Treatments in Overactive Bladder: An Update of a Systematic Review and Meta-Analysis

(2008) Christopher R. Chapple et al.   EUROPEAN UROLOGY

A Systematic Review and Meta-Analysis of Randomized Controlled Trials with Antimuscarinic Drugs for Overactive Bladder

(2008) Giacomo Novara et al.   EUROPEAN UROLOGY

Differential Pharmacological Effects of Antimuscarinic Drugs on Heart Rate: A Randomized, Placebo-controlled, Double-blind, Crossover Study With Tolterodine and Darifenacin in Healthy Participants ≥50 Years

(2008) Brian Olshansky et al.   JOURNAL OF CARDIOVASCULAR PHARMACOLOGY AND THERAPEUTICS